Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,897,661
  • Shares Outstanding, K 126,712
  • Annual Sales, $ 90,280 K
  • Annual Income, $ -66,340 K
  • 60-Month Beta 1.16
  • Price/Sales 47.90
  • Price/Cash Flow N/A
  • Price/Book 8.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.42
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +2.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.29 +1.55%
on 02/10/20
33.61 -8.48%
on 01/15/20
-3.21 (-9.45%)
since 01/14/20
3-Month
26.02 +18.22%
on 11/15/19
37.96 -18.97%
on 01/10/20
+4.69 (+17.99%)
since 11/14/19
52-Week
22.46 +36.95%
on 03/28/19
37.96 -18.97%
on 01/10/20
+3.58 (+13.17%)
since 02/14/19

Most Recent Stories

More News
MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / February 4, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today the initiation of an expanded access program (EAP)...

MOR : 30.76 (-2.29%)
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announces that it today has entered into a global collaboration and licensing agreement with Incyte Corporation to further develop...

MOR : 30.76 (-2.29%)
XNCR : 36.49 (-0.38%)
First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 27, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the first patient has been dosed in a phase 1b...

MOR : 30.76 (-2.29%)
MorphoSys AG: Corporate Calendar 2020

MorphoSys (NASDAQ:MOR) (FSE:MOR):

MOR : 30.76 (-2.29%)
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific...

MOR : 30.76 (-2.29%)
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results...

MOR : 30.76 (-2.29%)
NVS : 97.63 (-0.14%)
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced presentation of so far unpublished data on tafasitamab,...

MOR : 30.76 (-2.29%)
MorphoSys AG Reports Third Quarter 2019 Financial Results

MorphoSys AG Reports Third Quarter 2019 Financial Results

MOR : 30.76 (-2.29%)
NVS : 97.63 (-0.14%)
MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced topline results from the primary analysis of the retrospective...

MOR : 30.76 (-2.29%)
MorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR):

MOR : 30.76 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 31.32
1st Resistance Point 31.04
Last Price 30.76
1st Support Level 30.59
2nd Support Level 30.42

See More

52-Week High 37.96
Fibonacci 61.8% 32.04
Last Price 30.76
Fibonacci 50% 30.21
Fibonacci 38.2% 28.38
52-Week Low 22.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar